Cancer cells exploit this dysregulated protein degradation, mediated through the SMURF2-HIF1α pathway, to diminish cellular levels of proteins essential for the accurate repair of DNA damage or maintaining signal transduction fidelity, leading to an increased capacity for DNA repair and altered responsiveness to mutation-targeted therapies. This evidence concerns the gene SMURF2 and cancer.